Millennium Management LLC grew its position in shares of Vigil Neuroscience, Inc. (NASDAQ:VIGL - Free Report) by 23.3% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 343,814 shares of the company's stock after buying an additional 65,058 shares during the period. Millennium Management LLC owned 0.84% of Vigil Neuroscience worth $584,000 at the end of the most recent reporting period.
Several other large investors have also recently modified their holdings of VIGL. abrdn plc increased its position in shares of Vigil Neuroscience by 124.9% during the fourth quarter. abrdn plc now owns 528,472 shares of the company's stock valued at $898,000 after buying an additional 293,461 shares during the period. Cubist Systematic Strategies LLC grew its stake in Vigil Neuroscience by 53.0% during the fourth quarter. Cubist Systematic Strategies LLC now owns 24,120 shares of the company's stock valued at $41,000 after acquiring an additional 8,358 shares in the last quarter. Barclays PLC increased its holdings in Vigil Neuroscience by 43.6% during the 4th quarter. Barclays PLC now owns 64,049 shares of the company's stock worth $109,000 after acquiring an additional 19,436 shares during the period. Blair William & Co. IL bought a new stake in Vigil Neuroscience during the 4th quarter worth approximately $551,000. Finally, Northern Trust Corp lifted its stake in Vigil Neuroscience by 29.0% in the 4th quarter. Northern Trust Corp now owns 64,737 shares of the company's stock worth $110,000 after purchasing an additional 14,572 shares in the last quarter. Hedge funds and other institutional investors own 83.64% of the company's stock.
Vigil Neuroscience Price Performance
VIGL opened at $7.88 on Monday. The business's fifty day simple moving average is $3.40 and its 200 day simple moving average is $2.61. Vigil Neuroscience, Inc. has a 52 week low of $1.31 and a 52 week high of $7.95. The stock has a market cap of $367.78 million, a PE ratio of -3.83 and a beta of 3.43.
Vigil Neuroscience (NASDAQ:VIGL - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The company reported ($0.49) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.53) by $0.04. As a group, equities analysts anticipate that Vigil Neuroscience, Inc. will post -2.07 earnings per share for the current year.
Analyst Upgrades and Downgrades
A number of research firms have recently commented on VIGL. Citizens Jmp lowered shares of Vigil Neuroscience from a "strong-buy" rating to a "hold" rating in a research report on Thursday, May 22nd. Mizuho lowered Vigil Neuroscience from a "strong-buy" rating to a "hold" rating in a research note on Friday, May 23rd. Jefferies Financial Group cut Vigil Neuroscience to a "hold" rating in a research report on Thursday, May 22nd. William Blair cut Vigil Neuroscience from a "strong-buy" rating to a "hold" rating in a report on Thursday, May 22nd. Finally, JMP Securities reiterated a "market perform" rating on shares of Vigil Neuroscience in a research report on Thursday, May 22nd. Ten investment analysts have rated the stock with a hold rating, Based on data from MarketBeat, the company presently has a consensus rating of "Hold" and an average price target of $10.80.
Get Our Latest Stock Report on Vigil Neuroscience
About Vigil Neuroscience
(
Free Report)
Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.
Featured Articles
Want to see what other hedge funds are holding VIGL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vigil Neuroscience, Inc. (NASDAQ:VIGL - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Vigil Neuroscience, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vigil Neuroscience wasn't on the list.
While Vigil Neuroscience currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
